Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.66 |
| ▸ | KIT | P10721 | 5/20 | 0.66 |
| ▸ | LCK | P06239 | 4/20 | 0.66 |
| ▸ | KDR | P35968 | 4/20 | 0.66 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | SGK1 | O00141 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31367847 | 0.81 | MAPK14 (0.74) | MAPK14KITLCKKDRMAPK9 | |
| SCHEMBL2947386 | 0.80 | MAPK14 (1.00) | MAPK14KITLCKKDRMAPK9 | |
| SCHEMBL5492046 | 0.79 | MAPK14 (0.65) | MAPK14KITLCKKDRMAPK9 | |
| SCHEMBL3088468 | 0.78 | MAPK14 (0.68) | MAPK14KITLCKKDRMAPK9 | |
| SCHEMBL3083852 | 0.78 | MAPK14 (0.66) | MAPK14KITLCKKDRMAPK9 | |
| SCHEMBL3086445 | 0.77 | MAPK14 (0.73) | MAPK14KITLCKKDRMAPK9 | |
| SCHEMBL3087822 | 0.77 | MAPK14 (0.60) | MAPK14KITLCKKDRMAPK9 | |
| SCHEMBL5630096 | 0.76 | MAPK14 (0.87) | MAPK14LCKKDRCSF1RHSPB1 | |
| SCHEMBL5498393 | 0.75 | MAPK14 (0.60) | MAPK14LCKKDRSGK1CSF1R | |
| SCHEMBL6171249 | 0.75 | MAPK14 (0.71) | MAPK14KITLCKKDRMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | claimed |
| CN-100447137-C | P38 kinase inhibitors | NOVARTIS AG (CH) | 2008-12-31 | — | — | CN | claimed |
| EP-1687284-B1 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-29 | — | — | EP | claimed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | claimed |
| CN-1856480-A | P38 kinase inhibitors | NOVARTIS AG (CH) | 2006-11-01 | — | — | CN | claimed |
| EP-1687284-A2 | p-38 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2005012241-A2 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-10 | — | — | WO | claimed |
| US-20050020590-A1 | P-38 kinase inhibitors | NOVARTIS AG (CH) | 2005-01-27 | — | — | US | claimed |
| EP-2251333-A1 | Biphenyl derivatives as P-38 kinase inhibitors | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| EP-1990338-B1 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| EP-1990338-B1 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| CN-1856480-A | P38 kinase inhibitors | NOVARTIS AG (CH) | 2006-11-01 | — | — | CN | disclosed |
| EP-1687284-A2 | p-38 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005012241-A2 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-10 | — | — | WO | disclosed |
| US-20050020590-A1 | P-38 kinase inhibitors | NOVARTIS AG (CH) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111999-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | MAPK14 52/4885KIT 3756/4885LCK 214/4885 |
| US-20050020590-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | MAPK14 55/4885KIT 3797/4885LCK 146/4885 |
| US-20100234404-A1 | P-38 Kinase Inhibitors | MAPK8, MAP3K8, MAPK1 | MAPK14 52/4885KIT 3756/4885LCK 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.